Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Pokfulam, 102 Pok Fu Lam Road, Hong Kong, China.
Br J Surg. 2011 Sep;98(9):1292-300. doi: 10.1002/bjs.7583. Epub 2011 Jun 7.
There is a trend to offer liver transplantation to patients with hepatocellular carcinoma (HCC) with tumour status within the Milan criteria but with preserved liver function. This study aimed to evaluate the outcome of such patients following partial hepatectomy as primary treatment.
A retrospective analysis was performed on all adult patients with HCC and tumour status within the Milan criteria undergoing partial hepatectomy at a single centre from 1995 to 2008. Their outcomes were compared with those of similar patients having right-lobe living donor liver transplantation (LDLT) as primary treatment.
A total of 408 patients with HCC were enrolled. Some 384 patients with a solitary tumour 5 cm or less in diameter had a better 5-year survival rate than 24 patients with oligonodular tumours (2-3 nodules, each 3 cm or less in size) (70·7 versus 46 per cent; P = 0·025). Multivariable analysis identified younger age (65 years or less), lack of postoperative complications, negative resection margin, absent microvascular invasion and non-cirrhotic liver as predictors of favourable overall survival. The 5-year survival rate of 287 younger patients with chronic liver disease and R0 hepatectomy was 72·8 per cent, comparable to that of 81 per cent in 50 similar patients treated by LDLT (P = 0·093).
Partial hepatectomy for patients with HCC and tumour status within the Milan criteria achieved a satisfactory 5-year survival rate, particularly in younger patients with solitary tumours and R0 hepatectomy. Patients with oligonodular tumours have a worse survival and might benefit from liver transplantation.
目前存在一种趋势,倾向于为符合米兰标准的肝癌(HCC)患者提供肝移植治疗,这些患者的肿瘤状态在米兰标准内,但肝功能保留。本研究旨在评估这些患者行肝部分切除术作为初始治疗的结果。
对 1995 年至 2008 年在单中心行肝部分切除术的所有符合米兰标准的 HCC 且肿瘤状态在米兰标准内的成年患者进行回顾性分析。将其结果与接受右半活体肝移植(LDLT)作为初始治疗的类似患者的结果进行比较。
共纳入 408 例 HCC 患者。384 例单发肿瘤直径 5cm 或以下的患者 5 年生存率优于 24 例多结节肿瘤(2-3 个结节,每个结节直径 3cm 或以下)患者(70.7%比 46%;P=0.025)。多变量分析确定年龄(65 岁或以下)、无术后并发症、切缘阴性、无微血管侵犯和非肝硬化肝脏是总体生存良好的预测因素。287 例慢性肝病且 R0 肝切除的年轻患者 5 年生存率为 72.8%,与 50 例接受 LDLT 的类似患者的 81%相似(P=0.093)。
对于符合米兰标准的 HCC 患者,肝部分切除术可获得令人满意的 5 年生存率,尤其是对于单发肿瘤和 R0 肝切除的年轻患者。多结节肿瘤患者的生存率较差,可能受益于肝移植。